Your browser doesn't support javascript.
loading
Language impairment in the genetic forms of behavioural variant frontotemporal dementia.
Samra, Kiran; MacDougall, Amy M; Bouzigues, Arabella; Bocchetta, Martina; Cash, David M; Greaves, Caroline V; Convery, Rhian S; van Swieten, John C; Seelaar, Harro; Jiskoot, Lize; Moreno, Fermin; Sanchez-Valle, Raquel; Laforce, Robert; Graff, Caroline; Masellis, Mario; Tartaglia, Maria Carmela; Rowe, James B; Borroni, Barbara; Finger, Elizabeth; Synofzik, Matthis; Galimberti, Daniela; Vandenberghe, Rik; de Mendonça, Alexandre; Butler, Christopher R; Gerhard, Alexander; Ducharme, Simon; Le Ber, Isabelle; Tiraboschi, Pietro; Santana, Isabel; Pasquier, Florence; Levin, Johannes; Otto, Markus; Sorbi, Sandro; Rohrer, Jonathan D; Russell, Lucy L.
Afiliação
  • Samra K; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
  • MacDougall AM; Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
  • Bouzigues A; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
  • Bocchetta M; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
  • Cash DM; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
  • Greaves CV; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
  • Convery RS; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
  • van Swieten JC; Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
  • Seelaar H; Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
  • Jiskoot L; Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
  • Moreno F; Cognitive Disorders Unit, Department of Neurology, Donostia Universitary Hospital, San Sebastian, Spain.
  • Sanchez-Valle R; Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain.
  • Laforce R; Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.
  • Graff C; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Québec, QC, Canada.
  • Masellis M; Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Bioclinicum, Karolinska Institutet, Solna, Sweden.
  • Tartaglia MC; Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Solna, Sweden.
  • Rowe JB; Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada.
  • Borroni B; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
  • Finger E; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
  • Synofzik M; Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
  • Galimberti D; Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada.
  • Vandenberghe R; Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
  • de Mendonça A; Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
  • Butler CR; Fondazione Ca' Granda, IRCCS Ospedale Policlinico, Milan, Italy.
  • Gerhard A; University of Milan, Centro Dino Ferrari, Milan, Italy.
  • Ducharme S; Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Louvain, Belgium.
  • Le Ber I; Neurology Service, University Hospitals Leuven, Louvain, Belgium.
  • Tiraboschi P; Leuven Brain Institute, KU Leuven, Louvain, Belgium.
  • Santana I; Laboratory of Neurosciences, Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
  • Pasquier F; Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK.
  • Levin J; Department of Brain Sciences, Imperial College London, London, UK.
  • Otto M; Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK.
  • Sorbi S; Departments of Geriatric Medicine and Nuclear Medicine, University of Duisburg-Essen, Essen, Germany.
  • Rohrer JD; Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, QC, Canada.
  • Russell LL; McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.
J Neurol ; 270(4): 1976-1988, 2023 Apr.
Article em En | MEDLINE | ID: mdl-36538154
ABSTRACT

BACKGROUND:

Behavioural variant fronto-temporal dementia (bvFTD) is characterised by a progressive change in personality in association with atrophy of the frontal and temporal lobes. Whilst language impairment has been described in people with bvFTD, little is currently known about the extent or type of linguistic difficulties that occur, particularly in the genetic forms.

METHODS:

Participants with genetic bvFTD along with healthy controls were recruited from the international multicentre Genetic FTD Initiative (GENFI). Linguistic symptoms were assessed using items from the Progressive Aphasia Severity Scale (PASS). Additionally, participants undertook the Boston Naming Test (BNT), modified Camel and Cactus Test (mCCT) and a category fluency test. Participants underwent a 3T volumetric T1-weighted MRI, with language network regional brain volumes measured and compared between the genetic groups and controls.

RESULTS:

76% of the genetic bvFTD cohort had impairment in at least one language symptom 83% C9orf72, 80% MAPT and 56% GRN mutation carriers. All three genetic groups had significantly impaired functional communication, decreased fluency, and impaired sentence comprehension. C9orf72 mutation carriers also had significantly impaired articulation and word retrieval as well as dysgraphia whilst the MAPT mutation group also had impaired word retrieval and single word comprehension. All three groups had difficulties with naming, semantic knowledge and verbal fluency. Atrophy in key left perisylvian language regions differed between the groups, with generalised involvement in the C9orf72 group and more focal temporal and insula involvement in the other groups. Correlates of language symptoms and test scores also differed between the groups.

CONCLUSIONS:

Language deficits exist in a substantial proportion of people with familial bvFTD across all three genetic groups. Significant atrophy is seen in the dominant perisylvian language areas and correlates with language impairments within each of the genetic groups. Improved understanding of the language phenotype in the main genetic bvFTD subtypes will be helpful in future studies, particularly in clinical trials where accurate stratification and monitoring of disease progression is required.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Demência Frontotemporal / Transtornos do Desenvolvimento da Linguagem Limite: Humans Idioma: En Revista: J Neurol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Demência Frontotemporal / Transtornos do Desenvolvimento da Linguagem Limite: Humans Idioma: En Revista: J Neurol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido